Cancer Immunotherapy and Biomarkers

This paper identifies SLU7 as a pan-cancer target, showing its knockdown induces genomic instability and enhances immunogenicity, with effective tumor suppression in murine models.

The paper identifies CD4 memory T cell networks that form therapy-responsive immune niches in colorectal cancer liver metastases, determining chemotherapy response.

The paper identifies plasmacytoid dendritic cells (pDCs) in tumor-draining lymph nodes as a potential biomarker for predicting response to PD-L1 blockade therapy in melanoma.

This study characterizes tertiary lymphoid structures in endometrial cancer using multi-level transcriptomics, identifying transcriptional signatures and immune cell dynamics linked to ICI response.

This paper identifies and optimizes a potent small molecule LAG-3 inhibitor using DNA-encoded chemical library screening for cancer immunotherapy.

This paper identifies shared immune and epigenetic signatures between systemic lupus erythematosus and melanoma, revealing prognostic and therapeutic implications.

This study develops a releasable IL-15 superagonist that enhances antitumor immunity in cold tumors by activating CD25+CD8+ T cells while reducing toxicity.

The paper uses spatial proteomics to show IDO1's tumor-suppressive role in ovarian cancer by linking it to tryptophan metabolism and stress response pathways.

This study identifies an 82-gene transcriptomic signature predicting immune checkpoint inhibitor resistance in metastatic cutaneous melanoma using tumor and immune cell profiling.

The paper develops a spatial biomarker, DONUTS, to predict treatment response in lung cancer by analyzing the niche surrounding CD8+FoxP3+ T-cells.

Neoadjuvant IL-15 with PD-1 blockade expands lymph node clonal diversity and preserves stem-like CD8 T cell features, yielding superior antitumor efficacy, durable memory, and reduced metastatic recurrence.

The paper shows that high NUMB exon 9 inclusion in tumors is linked to immune evasion and metabolic changes that support tumor growth.

This study identifies LAG3+ CD8+ T cells as key effectors in bispecific antibody armed T cell therapy for HR+/HER2- breast cancer and shows how checkpoint inhibitors can enhance their anti-tumor function.

This study links TCR clonality in NSCLC to genetic mutations, immune phenotypes, immunotherapy response, and patient survival.

This study shows NLRC5 is essential for tumor immune surveillance and immunoediting, as its deficiency leads to increased tumor growth and reduced immune control.

This study shows that combining thermoneutral housing and timed PD-1 blockade significantly improves anti-tumor immunity and survival in a melanoma model.

This study shows that CD45 sequestration lowers T cell activation thresholds and enhances anti-tumor immunity when combined with IL-12 therapy in mouse models.

The paper identifies genetic determinants of CD8+ T cell receptor (TCR) repertoire in cancer patients before and after immune checkpoint blockade (ICB) treatment, finding associations with HLA alleles and treatment response.

This paper develops a distributed pipeline for immuno-oncology biomarker discovery using federated learning to integrate clinical and molecular data across institutions without sharing sensitive data.

This study shows glucocorticoids enhance anti-tumor immunity by inhibiting the GARP/TGF-β axis in melanoma, improving prognosis and response to immunotherapy.

This study distinguishes tissue-resident memory (TRM) and exhausted T (TEX) cells in tumors by analyzing their antigen reactivity, clonality, and functional outcomes.

This study identifies macrophage-driven NK cell infiltration during tumor regression and subsequent exclusion during residual disease as key factors in therapy resistance, highlighting macrophage-NK cell crosstalk as a therapeutic target.

This study investigates age-dependent tumor-immune interactions in pediatric cancer using mouse models and patient samples, finding that pediatric tumors have distinct immune profiles and poor response to immunotherapy, which can be improved by modulating the tumor microenvironment.

The paper shows that MSH6 regulates PD-L1 expression through SETD2 recruitment, and MSH6 KO cells have lower microsatellite instability despite higher mutational burden compared to MLH1 KO cells.

This study shows alcohol use reduces anti-PD1 immunotherapy efficacy in cancer patients and mouse models by impairing T cell function and anti-tumor immunity.

This study shows that inhibiting EZH2 in lung cancer enhances immunogenicity and TIL reactivity by altering the tumor microenvironment and T cell properties.

This study shows that TrIP deficiency in CD8 T cells enhances anti-tumor immunity by increasing inflammatory transcriptional profiles, T cell infiltration, and clonal diversity against tumors.

This study shows targeting mTORC2 in lung squamous cell carcinoma enhances anti-tumor immunity via the PSGL-1-VISTA axis by altering the tumor microenvironment and immune cell activation.